Get Stanford Medicine Center For Narcolepsy Sleep Inventory 2001-2024

A phase 3 study has found that an extended-release version of sodium oxybate reduces daytime sleepiness and attacks of muscle weakness in narcolepsy patients. A Stanford study shows that a new formulation of a narcolepsy medication is effective without a middle-of-the-night dose.

FDA granted final approval to Avadel Pharmaceutical's Lumryz (sodium oxybate), the first and only once-at-bedtime oxybate for people with narcolepsy. The extended-release formulation treats cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.

For people with mild to moderate sleepiness, or are often good choices. For people with more severe sleepiness, however, amphetamines or sodium oxybate often produce the best results.

Lumryz, is an extended-release sodium oxybate medication approved by the FDA on May 1, 2023, as the first and only once-at-bedtime treatment for cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.

Pitolisant, an H3R antagonist, and solriamfetol, a and reuptake inhibitor, are the most recently approved treatments for EDS associated with narcolepsy in the European Union (pitolisant) and the USA (pitolisant and solriamfetol).

This is called a sleep attack. These periods can last from a few seconds to a few minutes. They may happen after eating, while talking to someone, or during other situations. Most often, you wake up feeling refreshed.

The Center for Narcolepsy, Sleep and Health Research (CNSHR) at the College of Nursing (University of Illinois at Chicago [UIC]) was established in 1986 to help increase knowledge and awareness of narcolepsy and to provide information and support to those affected by this disorder.

FDA granted final approval to Avadel Pharmaceutical's Lumryz (sodium oxybate), the first and only once-at-bedtime oxybate for people with narcolepsy. The extended-release formulation treats cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.